Exploration of Treatment in Patients with T3 Rectal Cancer with EMVI

  • Youzhong Ke The First Hospital of Chongqing Medical University
  • Yuan Liu The First Hospital of Chongqing Medical University
  • Hao Zhang The First Hospital of Chongqing Medical University
  • Jiajun Hou The First Hospital of Chongqing Medical University
DOI: https://doi.org/10.18686/aem.v12i1.352
Keywords: Rectal Cancer, Neoadjuvant Chemoradiotherapy, EMVI, Long-Term Efficacy

Abstract

To explore the clinical efficacy of neoadjuvant chemoradiotherapy, combined with surgery and direct surgery in patients with stage T3 rectal cancer combined with EMVI. Method: The clinical data of patients with extragastrointestinal middle and low rectal cancer in the First Affiliated Hospital of Chongqing Medical University from January 2015 to May 2019 were retrospective reviewed, including 59 patients in the neoadjuvant treatment group (neoadjuvant chemoradiotherapy + surgical treatment) and 71 patients in the direct surgery group. Both groups underwent total rectal total membrane resection. Data and Methods:The concurrent chemotherapy regimens were all included in the XELOX regimen. The RT was performed by IMRT with D T 45 to 50.4 G y, from 1.8 to 2.0 G y each, for 25 to 28 sessions. Perioperative conditions, postoperative pathology and follow-up of the two groups were observed. Results: There was no significant difference in postoperative conditions (gastrointestinal function recovery time, postoperative drainage drainage, postoperative time of drainage removal) between the neoadjuvant treatment group and the direct surgery group (P> 0. 05); The length of postoperative hospital stay was significantly different (P <0.05); No significant operation time occurred between the neoadjuvant treatment group (264 min vs. 239 min) and the surgical group, (P> 0. 05)；The amount of intraoperative bleeding (85.7ml vs.110.0 ml), the number of lymph node dissection (11 vs. 13), the lymph node positive rate (27.12% vs.43.6%) betweenthe neoadjuvant treatment group and the direct surgery group had statistical significant (P＜0. 05); The 3-yearrecurrence-free survival (93.2 %) rate was higher in the neoadjuvant treatment group than in the direct surgery group (74.6 %), which was significant (P <0.05); The 3-year survival rate (98.30,% vs. 85.9 %) was significantly significant (P <0.05); There was no significant difference in the anal preservation rate (71.19% vs. 80.28%) (P> 0. 05). Conclusion: The neoadjuvant chemoradiotherapy improves the recurrence-free survival rate of locally advanced rectal cancer, and has no obvious effect on the postoperative complications rate, anal preservation rate and gastrointestinal function recovery.

References

[1] You, Y. Nancy, et al. "The American society of colon and rectal surgeons clinical practice guidelines for the management of rectal cancer." Diseases of the Colon & Rectum 63.9 (2020): 1191-1222.

[2] Glimelius, B., et al., Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2013. 24: p. vi81-vi88.

[3] Sohn, B., et al., MRI-detected extramural vascular invasion is an independent prognostic factor for synchronous metastasis in patients with rectal cancer. European Radiology, 2015. 25(5): p. 1347-1355.

[4] Bugg, W.G., et al., The prognostic significance of MRI-detected extramural venous invasion in rectal carcinoma. Clinical Radiology, 2014. 69(6): p. 619-623.

[5] Yang,Li,Study on the Efficacy of Neoadjuvant Radiochemotherapy in the Treatment of T3 Mid-low Rectal Cancer.2016.Second Military Medical University,MA thesis.

[6] Glynne-Jones, Rob. "Do t3 rectal cancers always need radiochemotherapy?." Early Gastrointestinal Cancers II: Rectal Cancer (2014): 95-115.

[7] Smith, N.J., et al., Prognostic significance of magnetic resonance imaging-detected extramural vascular invasion in rectal cancer. Br J Surg, 2008. 95(2): p. 229-36.

[8] Betge, J., et al., Intramural and extramural vascular invasion in colorectal cancer. Cancer, 2012. 118(3): p. 628-638.

[9] Siddiqui, M.R.S., et al., A meta-analysis comparing the risk of metastases in patients with rectal cancer and MRI-detected extramural vascular invasion (mrEMVI) vs mrEMVI-negative cases. British Journal of Cancer, 2017. 116(12): p. 1513-1519.

[10] Chand, M., et al., Adjuvant therapy decisions based on magnetic resonance imaging of extramural venous invasion and other prognostic factors in colorectal cancer. The Annals of The
Royal College of Surgeons of England, 2014. 96(7): p. 543-546.

[11] Gray, R., et al., Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet, 2007. 370(9604): p. 2020-9.

[12] O'Connell, M.J., et al., Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol, 2014. 32(18): p. 1927-34.

[13] Zhang, DY.Application value of MRI and spiral CT in preoperative staging diagnosis of rectal cancer [J]. Modern MedicalIimaging,2018,27(02):441-443.

[14] Mechera, R., et al., Lymph node yield after rectal resection in patients treated with neoadjuvant radiation for rectal cancer: A systematic review and meta-analysis. European Journal of Cancer, 2017. 72: p. 84-94.

[15] Govindarajan, A., et al., Challenging the feasibility and clinical significance of current guidelines on lymph node examination in rectal cancer in the era of neoadjuvant therapy. J Clin Oncol, 2011. 29(34): p. 4568-73.

[16] Tang.C,H, Chu.S,B, Shuai.H,J, Clinical study of neoadjuvant chemoradiotherapy combined with surgery in the treatment of stage T_3N_ + / T_4N_x rectal cancer[J].Journal of Clinical Oncology,2019,24(03):242-246.

[17] Hoare, D., A. Maw and S. Gollins, Does pre-operative chemoradiotherapy cause wound complications after abdominoperineal excision for rectal cancer? An observational study. International Journal of Surgery, 2013. 11(5): p. 395-399.

[18] Wang FJ, Chi B, Lin HM, et al. Effect of neoadjuvant chemoradiotherapy on anal preservation rate of different highly low rectal cancer and its prognostic factors[J]. Chinese Journal of Surgery, 2016, 54(06):419-423.

[19] Kopetz, Scott, et al. "Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy." Journal of clinical oncology 27.22 (2009): 3677.

[20] Oshi, M., et al., Higher Tumor Burden Neutralizes Negative Margin Status in Hepatectomy for Colorectal Cancer Liver Metastasis. Annals of Surgical Oncology, 2019. 26(2): p. 593-603.

[21] Jing WJ, Zhu JQ. Risk factor analysis and prediction model construction of liver metastasis after colorectal cancer.Chinese Journal of Clinical Oncology,2022. 49(01): Pages 26-30.

[22] Eichler, K., et al., Hepatic Arterial Infusion with Irinotecan in Patients with Liver Metastases of Colorectal Cancer: Results of an Extended Phase I Study. Chemotherapy, 2013. 59(1): p. 66-73.

[23] Bokey, E. L., et al. "Factors affecting survival after excision of the rectum for cancer." Diseases of the colon & rectum 40.1 (1997): 3-10.
Published
2023-03-21
Issue
Vol 12, No 1(2023)
Section
Original Research Article

Copyright (c) 2023 Youzhong Ke, Yuan Liu, Hao Zhang, Jiajun Hou

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear

Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.